INDIRECT COMPARISON OF DARATUMUMAB MONOTHERAPY VERSUS REAL-WORLD HISTORICAL CONTROL DATA IN PATIENTS WITH MULTIPLE MYELOMA WHO ARE HEAVILY PRE-TREATED AND HIGHLY REFRACTORY

被引：1
|
作者：
Diels, J. [1 ]
Lam, A. [2 ]
Ito, T. [3 ]
Ng, Y. [2 ]
Mehra, M. [2 ]
Khan, I [4 ]
机构：
[1] Janssen Hlth Econ & Market Access EMEA Stat & Mod, Beerse, Belgium
[2] Janssen Global Serv LLC, Raritan, NJ USA
[3] Janssen Hlth Econ & Market Access EMEA, High Wycombe, Bucks, England
[4] Janssen Res & Dev LLC, Raritan, NJ USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1659
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN37
引用
收藏
页码：A140 / A140
页数：1
相关论文
共 50 条
  • [31] Real-world clinical outcomes in patients with multiple myeloma treated with isatuximab after daratumumab treatment
    Kikuchi, Taku
    Tsukada, Nobuhiro
    Nomura, Moe
    Kasuya, Yuki
    Oda, Yuki
    Sato, Kota
    Takei, Tomomi
    Ogura, Mizuki
    Abe, Yu
    Suzuki, Kenshi
    Ishida, Tadao
    [J]. ANNALS OF HEMATOLOGY, 2023, 102 (06) : 1477 - 1483
  • [32] Carfilzomib-Based Regimens Are Efficacious and Well Tolerated in Heavily Pre-Treated Multiple Myeloma Patients: Real World Data from a Norwegian Cohort
    Lysen, Anna
    Haarstad, Ina
    Schjesvold, Fredrik H.
    [J]. BLOOD, 2018, 132
  • [33] Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting
    Tong, Juan
    Zhao, Na
    Hu, Xing
    Yao, Wen
    Cheng, Yaxin
    Zhou, Li
    Liu, Huilan
    Geng, Liangquan
    Sun, Zimin
    Zheng, Changcheng
    [J]. CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 5613 - 5621
  • [34] Panobinostat in combination with bortezomib and dexamethasone for heavily pre-treated myeloma: a UK real-world multi-centre cohort
    Maouche, N.
    Kishore, B.
    Bhatti, Z.
    Supratik, B.
    Karim, F.
    Sundararaman, S.
    Collings, F.
    Tseu, B.
    Leary, H.
    Ryman, N.
    Reddy, U.
    Vallance, G.
    Kothari, J.
    Djebbari, F.
    Ramasamy, K.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 121 - 122
  • [35] Real-world outcomes of belantamab mafodotin monotherapy in triple class refractory patients with multiple myeloma
    Ntanasis-Stathopoulos, Ioannis
    Malandrakis, Panagiotis
    Fotiou, Despina
    Migkou, Magdalini
    Roussou, Maria
    Eleutherakis-Papaiakovou, Evangelos
    Theodorakakou, Foteini
    Spiliopoulou, Vassiliki
    Kastritis, Efstathios
    Terpos, Evangelos
    Dimopoulos, Meletios
    Gavriatopoulou, Maria
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S203 - S204
  • [36] EFFECT OF DARATUMUMAB ON PNEUMONIA IN PATIENTS WITH MULTIPLE MYELOMA USING POPULATION BASED REAL-WORLD DATA
    Kim, Y.
    Kang, K. W.
    Suh, H. S.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S17 - S17
  • [37] Contemporary Use of VTD-PACE As Bridge Therapy in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma
    Kurish, Heena P.
    Row, Kerri
    Kurkowski, Austin
    Rice, Mikhaila
    Rudoni, Joslyn
    Khouri, Jack
    Mazzoni, Sandra
    Samaras, Christy J.
    Williams, Louis S.
    van Heeckeren, Willem
    Valent, Jason
    Anwer, Faiz
    [J]. BLOOD, 2022, 140 : 12496 - 12497
  • [38] Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma
    Dima, Danai
    Davis, James A.
    Ahmed, Nausheen
    Sannareddy, Aishwarya
    Shaikh, Hira
    Mahmoudjafari, Zahra
    Khouri, Jack
    Kaur, Gurbakhash
    Strouse, Christopher
    Valent, Jason
    Larry, Anderson D., Jr.
    Anwer, Faiz
    Abdallah, Al-Ola
    Hashmi, Hamza
    [J]. BLOOD, 2023, 142
  • [39] DURATION OF THERAPY IN US PATIENTS TREATED FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE REAL-WORLD
    Romanus, D.
    Raju, A.
    Yong, C.
    Seal, B.
    Farrelly, E.
    Noga, S.
    Jhaveri, M.
    Labotka, R.
    Blazer, M.
    Parameswaran, H.
    [J]. HAEMATOLOGICA, 2016, 101 : 538 - 539
  • [40] Selinexor, Daratumumab and Dexamethasone for Patients with Multiple Myeloma Previously Treated with Lenalidomide at First Relapse: A Real-World Study
    Zhai, Yingying
    Yan, Lingzhi
    Jin, Song
    Shang, Jingjing
    Shi, Xiaolan
    Yao, Weiqin
    Yan, Zhi
    Yan, Shuang
    Wu, De-pei
    Fu, Chengcheng
    [J]. BLOOD, 2023, 142
12345